Bolt Biotherapeutics, Inc. (BOLT): Results of Operations and Financial Condition
Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results • Cash b
How this was made
The 30-second read
Why it matters
The most tradable elements are (1) the stated cash balance and runway into 1Q 2027 and (2) the reiterated expectation that initial BDC-4182 clinical data will be released with Q3 2026 results. Q2 financials show lower R&D and G&A expenses year over year, consistent with restructuring and reduced activity.
Market read
This is a primary-source company update that can reset near-term expectations for the next clinical catalyst (Q3 2026 data) and informs risk around funding needs (runway into 1Q 2027).
What to watch
Cash runway is supportive, but the company also notes restructuring-driven expense declines, which may not persist; investors may scrutinize whether trial dosing/escalation changes could affect future burn.
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Operating losses and research and development spending declined from the prior-year quarter following restructuring, but collaboration revenue fell to $5,000 and the company reported cash expected to fund operations only into first quarter 2027. The key near-term catalyst is initial BDC-4182 clinical data expected with third quarter 2026 results.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenueGAAP | $5,000 | – | – |
| Research and development expensesGAAP | $5.1 million | – | – |
| General and administrative expensesGAAP | $2.4 million | – | – |
| Impairment chargesGAAP | $ 808 (in thousands) | – | – |
| Total operating expenseGAAP | $ 8,379 (in thousands) | – | – |
| Loss from operationsGAAP | $8.4 million | – | – |
| Interest income, netGAAP | $ 178 (in thousands) | – | – |
| Other income, netGAAP | $ 476 (in thousands) | – | – |
| Total other income (expense), netGAAP | $ 654 (in thousands) | – | – |
| Net lossGAAP | $ 7,720 (in thousands) | – | – |
| Net unrealized loss on marketable securitiesGAAP | $ 33 (in thousands) | – | – |
| Comprehensive lossGAAP | $ 7,753 (in thousands) | – | – |
| Net loss per share, basic and dilutedGAAP | $ (4.57 ) | – | – |
| Weighted-average shares outstanding, basic and dilutedGAAP | 1,690,529 | – | – |
| Six-month collaboration revenueGAAP | $ 31 (in thousands) | – | – |
| Six-month research and development expensesGAAP | $ 9,978 (in thousands) | – | – |
| Six-month general and administrative expensesGAAP | $ 5,220 (in thousands) | – | – |
| Six-month impairment chargesGAAP | $ 808 (in thousands) | – | – |
| Six-month total operating expenseGAAP | $ 16,006 (in thousands) | – | – |
| Six-month loss from operationsGAAP | $ 15,975 (in thousands) | – | – |
| Six-month net lossGAAP | $ 14,964 (in thousands) | – | – |
| Six-month net loss per share, basic and dilutedGAAP | $ (8.88 ) | – | – |
| Six-month net cash used in operating activitiesGAAP | $ 14,563 (in thousands) | – | – |
Third quarter 2026 and first quarter 2027 outlook
- NoteInitial clinical data from BDC-4182 Phase 1/2 study for patients with gastric and gastroesophageal cancer expected with third quarter 2026 results.
- NoteCash on hand is expected to fund operations into first quarter 2027.
What drove it
- The decrease in research and development expenses was mainly due to a decrease in salary and related expenses primarily as a result of restructuring and overall lower research and development activities.
- The decrease in general and administrative expenses was mainly due to a decrease in salary and related expenses primarily as a result of restructuring as well as lower consulting expenses.
- Revenue in the comparative periods was generated from services performed under the R&D collaborations as the company fulfills its performance obligations.
- The Phase 1/2 study is progressing with ongoing treatment of patients in Cohort 4 at the 4.0 mg/kg dose level.
Concerns
- Collaboration revenue was $5,000 for the quarter ended June 30, 2026, compared to $1.8 million for the same quarter in 2025.
- The company reported a net loss of $ 7,720 (in thousands) and loss from operations of $8.4 million for the quarter ended June 30, 2026.
- Cash on hand is expected to fund operations into first quarter 2027.
- The rest of the pipeline is currently on hold, including BDC-3042 and preclinical ISAC programs targeting CEA and PD-L1.
- The company recorded impairment charges of $ 808 (in thousands) during the quarter.
What to watch
- Initial clinical data from the BDC-4182 Phase 1/2 study expected with third quarter 2026 results.
- Progression of BDC-4182 patient treatment in Cohort 4 at the 4.0 mg/kg dose level.
- Cash runway expected to fund operations into first quarter 2027.
- Potential ability to partner the CEA ISAC and PD-L1 ISAC programs.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $18.1 million as of June 30, 2026.
- Cash and cash equivalents were $ 12,860 (in thousands) as of June 30, 2026, compared to $ 11,703 (in thousands) as of December 31, 2025.
- Short-term investments were $ 4,738 (in thousands) as of June 30, 2026, compared to $ 15,802 (in thousands) as of December 31, 2025.
- Long-term investments were $ 509 (in thousands) as of June 30, 2026, compared to $ 4,337 (in thousands) as of December 31, 2025.
- Restricted cash was $ 200 (in thousands) and restricted cash, non-current was $ 1,538 (in thousands) as of June 30, 2026.
- Total assets were $ 40,344 (in thousands) as of June 30, 2026, compared to $ 56,748 (in thousands) as of December 31, 2025.
- Total liabilities were $ 27,704 (in thousands) as of June 30, 2026, compared to $ 30,243 (in thousands) as of December 31, 2025.
- Total stockholders' equity was $ 12,640 (in thousands) as of June 30, 2026, compared to $ 26,505 (in thousands) as of December 31, 2025.
- Net cash used in operating activities was $ 14,563 (in thousands) for the six months ended June 30, 2026, compared to $ 22,962 (in thousands) for the six months ended June 30, 2025.
- Purchases of property and equipment were $ 13 (in thousands) for the six months ended June 30, 2026.
- Proceeds from sales of property and equipment were $ 717 (in thousands) for the six months ended June 30, 2026, compared to $ 963 (in thousands) for the six months ended June 30, 2025.
Analysis
Bolt Biotherapeutics reported a lower operating loss for the second quarter of 2026, with loss from operations of $8.4 million compared with $9.2 million in the same quarter in 2025. The improvement reflected lower research and development expenses of $5.1 million versus $7.5 million and lower general and administrative expenses of $2.4 million versus $3.5 million. Management attributed both expense reductions principally to restructuring-related lower salary and related costs, with lower research and development activity also affecting R&D and lower consulting costs affecting G&A. The quarter also included impairment charges of $ 808 (in thousands).
Management, verbatim
In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and gastroesophageal cancer. We are currently treating patients in Cohort 4. To date, BDC-4182 has been well tolerated, and we are seeing activity consistent with our immune-stimulating mechanism.
Willie Quinn, President and Chief Executive Officer
We expect to report initial clinical data from BDC-4182 with our third quarter 2026 results.
Willie Quinn, President and Chief Executive Officer
Not in the filing
stated, not guessed- Quarterly operating cash flow
- Free cash flow
- Debt balance
- Gross margin
- Non-GAAP financial metrics
- Quarter-over-quarter comparisons
- Financial revenue, expense, margin, EPS, or tax-rate guidance
- Capital return activity, including share repurchases and dividends
- Complete investing and financing cash flow information, because the filing text is truncated following the investing cash flow section
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Bolt Biotherapeutics filed an 8-K (Item 2.02) with Q2 2026 financial results and a business update for its lead BDC-4182 Phase 1/2 program targeting claudin 18.2 in gastric and gastroesophageal cancers.
Ticker impact
Bolt reported Q2 2026 financial results and said it expects initial BDC-4182 clinical data with its Q3 2026 results.
Likely volatility into the Q3 2026 data window; immediate reaction may hinge on cash runway reassurance versus limited clinical datapoint detail.
The filing is a primary disclosure (8-K with results and business update). It provides concrete runway (into 1Q 2027) and a specific upcoming catalyst (initial BDC-4182 data in Q3 2026), but does not include new efficacy/safety results yet.
Market effects
Adds another datapoint on clinical-stage biotech funding dynamics and the market’s sensitivity to upcoming early readouts.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited, as the update is company-specific and early-stage clinical timing-focused.
Counterpoint
The update emphasizes expectations for Q3 data but provides no new clinical efficacy or safety results, so the market may discount it if investors already priced the timeline.
Key entities
- issuerBolt Biotherapeutics, Inc.
Clinical-stage biopharmaceutical company reporting Q2 2026 results and updating BDC-4182 Phase 1/2 progress.
- clinical_programBDC-4182
First-in-class immune-stimulating antibody conjugate in Phase 1/2; initial clinical data expected with Q3 2026 results.
- executiveWillie Quinn
CEO who commented on BDC-4182 progress and expected timing of initial data.
